Exelixis, NBE join forces for discovery and development of ADCs for cancer

This article was originally published here

The agreement comes as Exelixis continues to build out its pipeline behind CABOMETYX (cabozantinib), its flagship product that is now a global oncology franchise. Under the terms of

The post Exelixis, NBE join forces for discovery and development of ADCs for cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply